CASP3 and breast carcinoma: Flow cytometric analyses of breast cancer cells treated with AG1024, gefitinib, or both, and stained with annexinV and propidium iodide (cells treated for 3 days) or with red–DEVD–FMK for caspase-3 activation (cells treated for 1 day) are shown in Fig. 3a,b.